Edgewise Therapeutics (EWTX) Cash from Operations (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Cash from Operations of 42543000.0 for Q1 2026, down 12.35% on a YoY basis from 48538167.4 in Q1 2025, and down 10.24% sequentially from 38592000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Cash from Operations (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Cash from Operations data on file, last reported at 42543000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 12.35% year-over-year to 42543000.0; the trailing twelve-month figure through Mar 2026 stood at 148493000.0 (down 25.53% YoY), and the FY2025 full-year result was 143816000.0, down 31.91% from the prior year.
- Cash from Operations declined to 42543000.0 in Q1 2026, from 38592000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 11855000.0 in Q4 2022 to a low of 42543000.0 in Q1 2026.
- A 5-year average of 25880588.24 and a median of 26830000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 126.32% in 2023 and declined 0.47% in 2024, its largest moves.
- Tracing EWTX's Cash from Operations over 5 years: stood at 11855000.0 in 2022, then sank by 126.32% to 26830000.0 in 2023, then slipped by 0.47% to 26957000.0 in 2024, then sank by 43.16% to 38592000.0 in 2025, then dropped by 10.24% to 42543000.0 in 2026.
- Business Quant data shows EWTX's Cash from Operations at 42543000.0 in Q1 2026, 38592000.0 in Q4 2025, and 34776000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | -42.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.54 Mn |
| Mar 31, 2026 | -42.54 Mn |
| Dec 31, 2025 | -38.59 Mn |
| Dec 31, 2025 | -38.59 Mn |
| Sep 30, 2025 | -34.78 Mn |
| Sep 30, 2025 | -34.78 Mn |
| Jun 30, 2025 | -32.58 Mn |
| Jun 30, 2025 | -32.58 Mn |
| Mar 31, 2025 | -37.87 Mn |
| Mar 31, 2025 | -37.87 Mn |
| Dec 31, 2024 | -26.96 Mn |
| Dec 31, 2024 | -26.96 Mn |
| Sep 30, 2024 | -27.37 Mn |
| Sep 30, 2024 | -27.37 Mn |
| Jun 30, 2024 | -26.10 Mn |
| Jun 30, 2024 | -26.10 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Dec 31, 2023 | -26.83 Mn |
| Dec 31, 2023 | -26.83 Mn |